Watch a trailer
Updates by Month
- June 2022
- May 2022
- April 2022
- February 2022
- December 2021
- November 2021
- October 2021
- August 2021
- July 2021
- June 2021
- March 2021
- February 2021
- December 2020
- November 2020
- October 2020
- September 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- September 2019
- August 2019
- July 2019
- June 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- January 2015
- December 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- August 2013
The Joint UK Society’s Working Group on Renal Denervation. Our initial response to the Medtronic Symplicity HTN3 announcement
Created - 06.02.2014
The Joint UK Society’s Working Group on Renal Denervation.
Our initial response to the Medtronic Symplicity HTN3 announcement.
Mark Caulfield1 (Chair), Mark de Belder2, Trevor Cleveland3, David Collier1, Indranil Das Gupta, John Deanfield4, Huon Gray5, Charles Knight5, Melvin Lobo1, Matthew Matson3, Jon Moss3, Neil Poulter1, Iain Simpson5, Bryan Williams1.
On behalf of the British Hypertension Society1, the British Cardiovascular Intervention Society2, the British Society for Interventional Radiology3, National Institute for Clinical Outcomes Research4, the British Cardiovascular Society5, and the Renal Association6.
Symplicity HTN3 Trial of renal denervation in resistant hypertension.
- Medtronic announced on January 9th 2014 that a large randomised controlled trial of renal denervation in 530 people with resistant hypertension using the unipolar Symplicity Catheter has not met the primary endpoint for blood pressure reduction.
- The study met the safety endpoint and there is no evidence of harm at 6 months.
- Medtronic has suspended its own regulatory trials in resistant hypertension worldwide while it assesses the results of Symplicity HTN3 and consults with international experts. This is a sensible approach as they have very similar designs. Trials in other conditions such as heart failure are continuing.
- The response of the other renal denervation device manufacturers is unclear at present but at least one (Covidien) has withdrawn its product from the market.
- There are no data available at this time other than information above.
The Joint UK Societies current perspective:
- Data from the trial will be reported at a forthcoming international meeting and in peer reviewed journals. To make a proper evaluation of the implications of this trial for renal denervation we need to thoroughly review the results of Symplicity HTN3 and not rush to uninformed conclusions.
- While we await the data from Symplicity HTN3, we recommend a temporary moratorium on renal denervation procedures for all cases as part of routine care in the NHS and private practice in the UK.
- We will make a further statement when the data is released.
- Our proposed temporary moratorium should not apply to clinical trials as there are many other technologies that are in development for renal denervation (including by Medtronic). Some randomised controlled trials are starting or underway and the UK is committed to leading, supporting and participating in well-designed trials. It is now even more important than ever that rigorously conducted randomised controlled trials are undertaken to assess the future role of renal denervation in the treatment of resistant hypertension.